Piper Sandler has resumed coverage of Supernus Pharmaceuticals with an overweight rating and a $47 price target, citing the recent merger with Indivior as a key driver for enhanced business development and M&A capabilities. The firm projects the combined entity's EBITDA to exceed $1 billion by 2027, driven by strong performance from key drugs like Sublocade and Qelbree, suggesting a positive outlook for the company's financial future and strategic flexibility.
Piper Sandler resuming coverage of Supernus Pharmaceuticals with an overweight rating and a $47 price target is a significant positive development for the company. The analyst's rationale centers on the recently completed merger with Indivior, which is expected to bolster the combined entity's business development and M&A capabilities. This news primarily affects Supernus Pharmaceuticals (SUPN) and, by extension, Indivior (INDV) as the merger partner. In the short term, this could lead to increased investor interest and a potential bump in SUPN's stock price due to the positive analyst sentiment. Long-term, the projected EBITDA exceeding $1 billion by 2027, driven by key drugs and financial flexibility for future transactions, presents a strong growth opportunity for the combined company. The key opportunity for traders lies in the potential for SUPN's stock to appreciate as the market digests this positive analyst coverage and the long-term growth prospects outlined.